Recommended reading:"The
Additional dose adjustments were made by the
Patients 1 and January 31, the oral calcitriol index date was the date CJASN 15: ccc–ccc, March, 2020 Vitamin D Conversion from IV to Oral, Thadhani et al
Owing to the above- cited reports regarding a potential survival advantage of paricalcitol-treated patients, we converted all HD patients in our large dialysis center from calcitriol
The baseline mean calcium level of 9
77)
These medications are synthetic vitamin D
Calcitriol was given twice daily, each dose is 0
Paricalcitol was administrated by three times a week before meeting the standard, after that altering to once weekly
We converted all HD patients in our large urban dialysis center from calcitriol to paricalcitol using a 1:3 conversion ratio, based on published data
, calcitriol, Hectorol (doxercalciferol), Zemplar (paricalcitol), where treatment failure is defined as at least a 2-month trial of each; and Member has therapeutic failure, contraindication or intolerance of cinacalcet (Sensipar), where treatment failure is defined as at least a 6-month trial of cinacalcet However, daily 0
Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size Thirty HD with SHPT treated previously with calcitriol for at least 6 months were switched to paricalcitol (1:4 conversion ratio)
Titrate up or down by 2-4 mcg q2-4Weeks
025) and achieved a mean reduction of PTH into a desired therapeutic range (100 to 300 pg/mL) at approximately week 18, whereas the calcitriol-treated patients, as a group, were unable
Paricalcitol and calcitriol result in similar ≥50% reduction of parathyroid hormone, calcium concentration, phosphate concentration, calcium phosphate, alkaline phosphatase, hypercalcemia, adverse events, and serious adverse events for secondary hyperparathyroidism in dialysis patients
Supply of vitamin D depends mainly on exposure to UV rays of the sun for conversion
ZEMPLAR is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis (1)
6 6 6 percent of patients in the oral calcitriol versus IV vitamin D group that had average iPTH values above 600 pg/ml
Headquarters DaVita Clinical Research ® 825 South 8th Street, Suite 300 Minneapolis, MN 55404
Forty patients with calcitriol-resistant and/or calcitriol-intolerant SHPT were included